Novo Nordisk Gains On UK Health Regulator Nod For Higher Wegovy Dose

Stock Track
01/16

U.S.-listed shares of Danish drugmaker Novo Nordisk rise 6% premarket.

The UK health regulator has approved a higher 7.2 mg weekly dose of Novo's Wegovy for obesity patients.

Newer studies found the 7.2 mg dose can achieve around 20% weight loss.

The new dose is given as three separate injections and exceeds the previous 2.4 mg limit.

NVO fell ~42% in 2025.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10